JB Chemicals & Pharmaceuticals Ltd. (JB Pharma) reported fourth quarter net profit grew marginally to ₹88 crore from ₹85 crore within the year-earlier interval, up 4%.
Revenue elevated to ₹762 crore from ₹625 crore a year-earlier, up 22%.
For the monetary 12 months 2022-23, the corporate recorded net profit of ₹410 crore as in contrast with ₹386 crore within the earlier 12 months, up 6%. Revenue elevated to ₹3,149 crore from ₹2,424 crore, registering a progress of 30%.
Nikhil Chopra, CEO and Wholetime Director, JB Pharma mentioned, “Our market-beating performance in India is pivoted around big brands becoming bigger, and significant demand acceleration in the acquired portfolio.”
“Each of our top 5 brands have ascended through the ranks. Our performance in the International business has seen commendable gains amidst a challenging business environment. International formulations clocked mid-teens growth for the quarter,” he mentioned.
“While we are cautious of the inflationary environment our efforts are aimed at executing well, with productivity and cost optimisation as drivers, in order to deliver improved operating margins,” he added.
